

Intravacc, EpiVax to develop novel COVID-19 vaccine

03 June 2020 | News

Combines Intravacc's unique OMV delivery platform with synthetically produced COVID-19 epitopes from EpiVax' immunoinformatics toolbox



The Netherlands-based Intravacc, one of the world's leading translational research and development vaccine institutes, with an extensive track record in developing viral and bacterial vaccines, and US based EpiVax, a biotechnology company based in Providence with expertise in developing vaccines and therapeutics, announce that they have entered into a collaboration agreement to further progress an novel vaccine against COVID-19, based on Intravacc's proprietary Outer Membrane Vesicles (OMV) technology platform.

For this joint research project, Intravacc will combine its safe and immunogenic OMV delivery platform with synthetically produced COVID-19 epitopes (protein allergens), designed and optimized by EpiVax using advanced immunoinformatics tools, in order to generate a safe and highly effective T-cell response against SARS-CoV-2 and related coronaviruses.

Pre-clinical studies will start immediately so as to select the best candidate peptides for the vaccine. Intravacc will utilize its in-house pilot-scale facility for the GMP production of the OMV-peptide vaccine, for clinical (phase I) studies expecting to start in Q4 2020.